Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study

References

• Rubsamen PE, Gass JM. Vogt-koyanagi-harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–687. doi:10.1001/archopht.1991.01080050096037.
   PubMedGoogle Scholar
• Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol. 2000;11:437–442. doi:10.1097/00055735-200012000-00009.
   PubMedGoogle Scholar
• Herbort CP Jr., Abu El Asrar AM, Takeuchi M, et al. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Int Ophthalmol. 2019;39:1419–1425. doi:10.1007/s10792-018-0949-4.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr., Tugal-Tutkun I, Abu-El-Asrar A, et al. Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review. Eye (Lond). 2022; 36:29–43.
   PubMed Web of Science ®Google Scholar
• Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2002;42:13–23. doi:10.1097/00004397-200201000-00004.
   PubMedGoogle Scholar
• Shindo Y, Ohno S, Yamamoto T, et al. Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanagi-Harada’s disease. Hum Immunol. 1994;39:169–176. doi:10.1016/0198-8859(94)90257-7.
   PubMed Web of Science ®Google Scholar
• Sonoda KH, Hasegawa E, Namba K, et al. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65:184–190. doi:10.1007/s10384-020-00809-1.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr., Abu El Asrar AM, Yamamoto JH, et al. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol. 2017;37:1383–1395. doi:10.1007/s10792-016-0395-0.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513. doi:10.1016/S0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599–606. doi:10.1016/S0002-9394(01)00937-0.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:e486–493. doi:10.1111/aos.12127.
   PubMed Web of Science ®Google Scholar
• Sakata VM, da Silva FT, Hirata CE, et al. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2015;253:785–790. doi:10.1007/s00417-014-2904-z.
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Sugita S, Sagawa K, et al. Cytokine production by T cells infiltrating in the eye of uveitis patients. Jpn J Ophthalmol. 1998;42:262–268. doi:10.1016/S0021-5155(98)00016-1.
   PubMed Web of Science ®Google Scholar
• Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14–18. doi:10.1016/j.cyto.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425–6440. doi:10.1002/jcp.26429.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796.e783. doi:10.1016/j.ophtha.2013.09.048.
   PubMed Web of Science ®Google Scholar
• Couto C, Schlaen A, Frick M, et al. Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2018;26:485–489. Epub 2016 Oct 24. doi:10.1080/09273948.2016.1236969.
   PubMed Web of Science ®Google Scholar
• Flores-Robles BJ, Blanco-Madrigal J, Sanabria-Sanchinel AA, et al. Anti-TNFalpha therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome. Eur J Rheumatol. 2017;4:226–228. doi:10.5152/eurjrheum.2017.160085.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486. doi:10.1136/bjophthalmol-2012-302292.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with Adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581. doi:10.1016/j.ophtha.2012.02.018.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Takayama K, Obata H, Takeuchi M. Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy. Ocul Immunol Inflamm. 2020;28:509–512. doi:10.1080/09273948.2019.1603312.
   PubMed Web of Science ®Google Scholar
• Su E, Oza VS, Latkany P. A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with Adalimumab. J Formos Med Assoc. 2019;118:945–950. doi:10.1016/j.jfma.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Jeroudi A, Angeles-Han ST, Yeh S. Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014;45:332–334. doi:10.3928/23258160-20140709-09.
   PubMed Web of Science ®Google Scholar
• Kwon HY, Woo SJ. A case of recurrent Vogt-Koyanagi-Harada disease successfully treated with Adalimumab in young female adult patient. Korean J Ophthalmol. 2020;34:92–93. doi:10.3341/kjo.2019.0052.
   PubMedGoogle Scholar
• Hiyama T, Harada Y, Kiuchi Y. Clinical characteristics and efficacy of Adalimumab and low-dose methotrexate combination therapy in patients With Vogt–Koyanagi–Harada disease. Front Med (Lausanne). 2022;8. doi:10.3389/fmed.2021.730215.
   Web of Science ®Google Scholar
• Nishisho R, Kusuhara S, Sotani N, et al. Changes in choroidal imaging parameters following Adalimumab therapy for refractory noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2021;259:1273–1280. doi:10.1007/s00417-020-05032-9.
   PubMed Web of Science ®Google Scholar
• Urzua CA, Herbort CP Jr., Takeuchi M, et al. Vogt-Koyanagi-Harada (VKH) disease: step-by-step approach since 1906 to better understanding of the clinicopathology, immunopathology, diagnosis and management: a brief overview of the essentials. J Ophthalmic Inflamm Infect. 2022; 12:17. doi:10.1186/s12348-022-00293-3
   PubMed Web of Science ®Google Scholar
• Papasavvas I, Herbort CP Jr. Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye. J Ophthalmic Inflamm Infect. 2021;11:6. doi:10.1186/s12348-021-00237-3.
   PubMed Web of Science ®Google Scholar
• Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol. 2007;27:173–182. doi:10.1007/s10792-007-9060-y.
   PubMedGoogle Scholar
• AlBloushi AF, Herbort CP Jr., Abu El-Asrar AM. Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement. Int Ophthalmol. 2021;41:4187–4195. doi:10.1007/s10792-021-01989-6.
   PubMed Web of Science ®Google Scholar
• Bernasconi O, Papadia M, Herbort CP. Sensitivity of laser flare photometry compared to slit-lamp cell evaluation in monitoring anterior chamber inflammation in uveitis. Int Ophthalmol. 2010;30:495–500.
   PubMedGoogle Scholar
• Ozdogan Erkul S, Kapran Z, Uyar OM. Quantitative analysis of subfoveal choroidal thickness using enhanced depth imaging optical coherence tomography in normal eyes. Int Ophthalmol. 2014;34:35–40. doi:10.1007/s10792-013-9787-6.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M, et al. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539–552.
   PubMedGoogle Scholar
• Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, et al. Chronic recurrent Vogt-Koyanagi-Harada disease and development of ‘Sunset glow fundus’ predict worse retinal sensitivity. Ocul Immunol Inflamm. 2017;25:475–485. doi:10.3109/09273948.2016.1139730.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Jaffe GJ, Fortin E, et al. Long-term safety and efficacy of Adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021;128:899–909. doi:10.1016/j.ophtha.2020.10.036.
   PubMed Web of Science ®Google Scholar
• Tang Lee Say TL, Yang V, Fingret JM, et al. Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 2021;6:e000819. doi:10.1136/bmjophth-2021-000819.
   PubMed Web of Science ®Google Scholar
• Aden U, Favrais G, Plaisant F, et al. Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFalpha pathway and protection by etanercept. Brain Behav Immun. 2010;24:747–758. doi:10.1016/j.bbi.2009.10.010.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr., Tugal-Tutkun I, Khairallah M, et al. Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area. Int Ophthalmol. 2020;40:2423–2433. doi:10.1007/s10792-020-01417-1.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhou H, Yang P, et al. Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2008;92:182–185. doi:10.1136/bjo.2007.128967.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Keino H, Okada AA, et al. Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease. Retina. 2012;32:2061–2069. doi:10.1097/IAE.0b013e318256205a.
   PubMed Web of Science ®Google Scholar
• Nakai K, Gomi F, Ikuno Y, et al. Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2012;250:1089–1095. doi:10.1007/s00417-011-1910-7.
   PubMed Web of Science ®Google Scholar
• Jap A, Chee SP. The role of enhanced depth imaging optical coherence tomography in chronic Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2017;101:186–189. doi:10.1136/bjophthalmol-2015-308091.
   PubMed Web of Science ®Google Scholar
• da Silva FT, Sakata VM, Nakashima A, et al. Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2013;97:70–74. doi:10.1136/bjophthalmol-2012-302089.
   PubMed Web of Science ®Google Scholar
• Murata T, Sako N, Takayama K, et al. Identification of underlying inflammation in Vogt-Koyanagi-Harada disease with sunset glow fundus by multiple analyses. J Ophthalmol. 2019;2019:3853794. doi:10.1155/2019/3853794.
   PubMed Web of Science ®Google Scholar
• Balci O, Gasc A, Jeannin B, et al. Enhanced depth imaging is less suited than indocyanine green angiography for close monitoring of primary stromal choroiditis: a pilot report. Int Ophthalmol. 2017;37:737–748. doi:10.1007/s10792-016-0303-7.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to Adalimumab: relationship to anti-Adalimumab antibodies and serum Adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–926. doi:10.1136/ard.2006.065615.
   PubMed Web of Science ®Google Scholar